☰
- Copyright Finance TV Pty Ltd
- ABN 31 117 966 328
- Use of Our Content
- Disclaimer
- Privacy Policy
Mesoblast (ASX:MSB) reports a net loss US$45.3 million for nine months
28/05/2020 10:40:00
Mesoblast (ASX:MSB) the company that develops cellular medicines for inflammatory diseases, has reported a net loss of $US45.3 million in the nine months to the end of March.
This a 34 per cent reduction compared with US$69.1 million in the same corresponding period is driven by a 113 per cent increase in total revenues and 15 per cent decrease in research and development spend.
They will continue with trials for Remestemcel-L for the treatment of COVID-19.
During the period March-April 2020, 12 ventilator-dependent patients with moderate/severe COVID-19 ARDS were treated with two infusions of remestemcel-L.
Nine patients successfully came off ventilator support at a median of 10 days and were discharged from hospital.
Shares in Mesoblast (ASX:MSB), are trading 4.43 per cent higher at $4.01.
☰Home (All News)Finance NewsInterviewsStock WatchCompany...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PPK (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
-0.080(15.1%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 53.0¢ | 45.0¢ | $95.35K | 203.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 283 | 45.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.0¢ | 3290 | 2 |
View Market Depth
| Last trade - 13.41pm 16/08/2024 (20 minute delay) ? |
| PPK (ASX) Chart |